Cue Biopharma to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
- Company to host Investor Update call on
June 14, 2023to review and discuss the clinical progress and associated data presented at ASCO
The poster will highlight the company’s lead clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics, CUE-101, for the treatment of patients with human papilloma virus (HPV16+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) as a monotherapy and in combination with pembrolizumab (KEYTRUDA®).
The Company will host an Investor Update call on
Title: A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.
Abstract Number: 6013
Session: Head and Neck Cancer
Poster Session Display Date and Time:
Presenter: Christine Chung, M.D.,
Poster Discussion Session Date and Time:
The poster will be available in the Investor & Media section of the Company’s website at www.cuebiopharma.com under Scientific Publications and Presentations, following the presentation.
About Cue Biopharma
Headquartered in Boston, Massachusetts, we are led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.
For more information please visit www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.
Senior Director, Corporate Communications
Source: Cue Biopharma, Inc.